Sanara MedTech, Inc. (SMTI)
Stock Price:
$33.93 USD
5.94 (21.22%)
Updated November 27, 1:00 PM EST - Market closed
Key Info
| Market Cap |
213.55M |
| Revenue (ttm) |
14.15M |
| Net Income (ttm) |
-5.57M |
| Shares Out |
6.29M |
| EPS (ttm) |
-1.06 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| Dividend |
n/a |
| Dividend Yield |
n/a |
Stock Quote
| Trading Day |
November 27 |
| Last Price |
$33.93 |
| Previous Close |
$27.99 |
| Change ($) |
5.94 |
| Change (%) |
21.22% |
| Day's Open |
33.93 |
| Day's Range |
28.60 - 33.93 |
| Day's Volume |
3,509 |
| 52-Week Range |
28.17 - 35.01 |
More Stats
| Market Cap |
213.55M |
| Enterprise Value |
212.53M |
| Earnings Date (est) |
Jan 1, 1970 |
| Ex-Dividend Date |
n/a |
| Shares Outstanding |
6.29M |
| Float |
n/a |
| EPS (basic) |
-1.29 |
| EPS (diluted) |
-1.06 |
| FCF / Share |
-0.70 |
| Dividend |
n/a |
| Dividend Yield |
n/a |
| Earnings Yield |
n/a |
| FCF Yield |
n/a |
| Payout Ratio |
n/a |
| Shares Short |
5,354 |
| Short Ratio |
0.83 |
| Short % of Float |
n/a |
| Beta |
2.34 |
| PE Ratio |
n/a |
| Forward PE |
n/a |
| P/FCF Ratio |
n/a |
| PS Ratio |
15.09 |
| PB Ratio |
36.48 |
| Revenue |
14.15M |
| Operating Income |
-5.65M |
| Net Income |
-5.57M |
| Free Cash Flow |
-4.35M |
| Net Cash |
1.03M |
| Net Cash / Share |
0.16 |
| Gross Margin |
74.61% |
| Operating Margin |
-39.89% |
| Profit Margin |
-39.40% |
| FCF Margin |
-30.74% |
| ROA |
-50.53% |
| ROE |
-311.36% |
| ROIC |
-292.10% |
Stats based on trailing-twelve-month (ttm) numbers.
Analyst Forecasts
Analyst Ratings (0)
| Buy |
0 |
| Overweight |
0 |
| Hold |
0 |
| Underweight |
0 |
| Sell |
0 |
*No analysts have provided price targets for this stock.
Financial Performance
Financial numbers in millions USD.
Financial Overview
| Year | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|
| Revenue | 11.77 | 5.84 | 6.30 | 5.51 | 3.37 | 2.63 | 1.73 | 1.17 | 2.21 | 0.91 |
| Revenue Growth | 101.56% | -7.41% | 14.47% | 63.33% | 28.09% | 52.49% | 47.11% | -46.89% | 142.71% | - |
| Gross Profit | 10.56 | 5.33 | 5.50 | 4.56 | 2.48 | 1.83 | 0.93 | 0.38 | 1.41 | 0.37 |
| Operating Income | -2.74 | -0.50 | 0.12 | -0.27 | -0.96 | -2.06 | -2.93 | -5.42 | -5.01 | -2.48 |
| Net Income | -2.81 | -0.60 | 0.33 | -0.42 | -1.34 | -2.28 | -4.15 | -1.85 | -12.74 | -6.64 |
| Shares Outstanding | 2.13 | 2.17 | 1.11 | 1.09 | 1.07 | 0.88 | 0.78 | 0.63 | 0.55 | 0.36 |
| Earnings Per Share | -1.32 | - | - | -1.00 | -2.00 | -3.00 | -5.00 | -3.00 | -23.00 | -19.00 |
| Operating Cash Flow | -2.17 | 0.28 | -0.14 | 0.41 | -1.20 | -1.69 | -1.82 | -1.23 | -0.34 | -1.49 |
| Capital Expenditures | -0.18 | -0.01 | -0.04 | - | -0.01 | -0.01 | -0.03 | - | - | - |
| Free Cash Flow | -2.35 | 0.27 | -0.18 | 0.41 | -1.21 | -1.69 | -1.85 | -1.23 | -0.34 | -1.49 |
| Cash & Equivalents | 6.61 | 0.18 | 0.46 | 0.83 | 0.18 | 0.52 | 0.04 | 0.05 | 0.96 | 0.06 |
| Total Debt | 2.10 | - | 1.20 | 1.62 | 1.82 | 1.61 | 1.70 | 2.42 | 1.37 | 2.58 |
| Net Cash / Debt | 4.51 | 0.18 | -0.74 | -0.78 | -1.64 | -1.08 | -1.66 | -2.37 | -0.40 | -2.52 |
| Assets | 11.12 | 1.71 | 2.22 | 2.17 | 1.39 | 1.50 | 0.98 | 1.39 | 3.83 | 6.78 |
| Liabilities | 4.72 | 1.12 | 2.12 | 2.59 | 2.66 | 2.32 | 3.45 | 5.20 | 7.69 | 6.23 |
| Book Value | 6.61 | 0.59 | 0.10 | -0.42 | -1.27 | -0.83 | -2.47 | -3.81 | -3.86 | 0.56 |
Numbers in millions USD, except per-share numbers.
Company Details
| Full Name |
Sanara MedTech, Inc. |
| Country |
United States |
| Employees |
38 |
| CEO |
J. Michael Carmena |
Stock Information
| Ticker Symbol |
SMTI |
| Stock Exchange |
NASDAQ |
| Sector |
Healthcare |
| Industry |
Medical Care Facilities |
| Unique Identifier |
NASDAQ: SMTI |
Description
Sanara MedTech develops, markets, and distributes wound and skin care products to physicians, hospitals, clinics, and post-acute care settings in the United States. The company offers CellerateRX Surgical Activated Collagen Adjuvant powder that helps in the natural wound healing process; Biako¯s Antimicrobial Skin & Wound Cleanser, a patented wound cleansing spray that disrupts extracellular polymeric substances to eradicate biofilm; and Biako¯s Antimicrobial Skin & Wound Irrigation Solution that works to irrigate and remove microbes from the wound bed to help eliminate planktonic, immature, and mature biofilms. It also provides Biako¯s Antimicrobial Wound Gel, a patented gel that synergistically disrupts extracellular polymeric substances to help eliminate biofilm microbes in the gel to help in wound healing; HYCOL Hydrolyzed Collagen, an additive free Type I bovine collagen that offers hydrolyzed collagen fragments to the wound bed that are a fraction of the size of native collagen; and PULSAR II Advanced Wound Irrigation Debridement System, a portable and no touch hydro-mechanical debridement system that removes bacteria and necrotic tissue without disrupting healthy tissue. The company was formerly known as WNDM Medical Inc. and changed its name to Sanara MedTech Inc. in May 2019. Sanara MedTech Inc. was incorporated in 2001 and is based in Fort Worth, Texas.